SCHEMBL723544

SCHEMBL723544

COc1ccc(-c2ccnc3cc(-c4cc(OC)c(OC)c(OC)c4)oc23)c(-n2cccn2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4C Q08493 2/20 0.39
JAK2 O60674 2/20 0.36
JAK1 P23458 2/20 0.36
GAK O14976 2/20 0.35
RIPK2 O43353 2/20 0.35
COQ8A Q8NI60 2/20 0.35
NLK Q9UBE8 2/20 0.35
TUBB4A P04350 2/20 0.35
TUBB P07437 2/20 0.35
TUBA3C P0DPH7 2/20 0.35
TUBA1B P68363 2/20 0.35
TUBA4A P68366 2/20 0.35
TUBB4B P68371 2/20 0.35
TUBB3 Q13509 2/20 0.35
TUBB2A Q13885 2/20 0.35
TUBB8 Q3ZCM7 2/20 0.35
TUBA3E Q6PEY2 2/20 0.35
TUBA1A Q71U36 2/20 0.35
TUBA1C Q9BQE3 2/20 0.35
TUBB6 Q9BUF5 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723261 0.83 PDE4C (0.43) PDE4CJAK2JAK1GAKRIPK2
SCHEMBL723093 0.77 PDE4C (0.55) PDE4CJAK2JAK1SYKPTGES
SCHEMBL723294 0.77 PDE4C (0.47) PDE4CJAK2JAK1GAKRIPK2
SCHEMBL723027 0.76 PTGES (0.47) PDE4CJAK2JAK1GAKRIPK2
SCHEMBL722839 0.75 PDE4C (0.51) PDE4CJAK2JAK1TUBB4ATUBB
SCHEMBL724141 0.75 PDE4C (0.48) PDE4CJAK2JAK1SYKPTGES
SCHEMBL722312 0.75 JAK2 (0.48) PDE4CJAK2JAK1TUBB4ATUBB
SCHEMBL723585 0.75 PDE4C (0.51) PDE4CJAK2JAK1GAKRIPK2
SCHEMBL724908 0.74 PDE4C (0.53) PDE4CJAK2JAK1SYKPTGES
SCHEMBL723790 0.74 PDE4C (0.47) PDE4CJAK2JAK1SYKPTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PDE4C 2858/4885JAK2 14/4885JAK1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.